CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 4,199	$ 5,571
Marketable Securities, Current	1,277	1,864
Receivables	3,672	3,390
Inventories	1,304	1,560
Deferred income taxes	1,892	1,644
Prepaid expenses and other	502	470
Assets held-for-sale, Current	210	109
Total Current Assets	13,056	14,608
Property, plant and equipment	4,363	4,417
Goodwill	6,976	7,027
Other intangible assets	1,563	1,753
Deferred income taxes	577	915
Marketable Securities, Noncurrent	4,632	4,408
Other assets	787	621
Total Assets	31,954	33,749
Current Liabilities:
Short-term borrowings	755	590
Accounts payable	1,839	2,487
Accrued expenses	2,103	2,459
Deferred income	939	1,167
Accrued rebates and returns	1,067	851
Income taxes payable	98	262
Dividends payable	634	645
Total Current Liabilities	7,435	8,461
Pension, postretirement and postemployment liabilities	727	1,115
Deferred income	667	770
Income taxes payable	744	560
Other liabilities	475	618
Long-term debt	6,615	7,242
Total Liabilities	$ 16,663	$ 18,766
Commitments and contingencies (Note 19)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,178 in 2015 and 4,212 in 2014, liquidation value of $50 per share	$ 0	$ 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2015 and 2014	221	221
Capital in excess of par value of stock	1,363	1,507
Accumulated other comprehensive loss	(2,173)	(2,425)
Retained earnings	32,361	32,541
Less cost of treasury stock - 541 million common shares in 2015 and 547 million in 2014	(16,649)	(16,992)
Total Bristol-Myers Squibb Company Shareholders' Equity	15,123	14,852
Noncontrolling interest	168	131
Total Equity	15,291	14,983
Total Liabilities and Equity	$ 31,954	$ 33,749